OncoMatch/Clinical Trials/NCT02443831
CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Is NCT02443831 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including CD19+CD22 CAR T-cells and Lymphodepletion with Fludarabine for acute lymphoblastic leukemia.
Treatment: Lymphodepletion with Fludarabine · Lymphodepletion with Cyclophosphamide · CD19+CD22 CAR T-cells — This study aims to evaluate the safety, efficacy and duration of response of CD19+CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in children with high risk, relapsed CD19+ and CD22+ acute lymphoblastic leukaemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 bcr-abl1 fusion
Required: CD19 expression (positive)
Required: CD22 expression (positive)
Required: KMT2A (MLL) rearrangement
Required: TCF3 tcf3-hlf rearrangement
Required: TCF3 tcf3-pbx1 rearrangement
Excluded: CD19 wild-type
Excluded: CD22 wild-type
Demographics
Lab requirements
Kidney function
creatinine > 3 x upper limit of normal
Liver function
bilirubin > 3 x upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT02443831 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ABL1?
Yes, ABL1 bcr-abl1 fusion is a required biomarker for enrollment.
Does this trial require CD19?
Yes, CD19 expression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 expression is a required biomarker for enrollment.
Are patients with CD19 alterations eligible?
No. CD19 wild-type is an exclusion criterion.
Are patients with CD22 alterations eligible?
No. CD22 wild-type is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 24 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify